SHIVA AHMADI: Open Payments
NPI 1356873715 · COSTA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,903 in 186 payments from 23 companies in 2025. Trend: 2023 $138 · 2024 $335 · 2025 $4,903
Food & beverage: $4,903
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 19 | $572 |
| ABBVIE INC. | 18 | $546 |
| Neurocrine BioSciences, Inc. | 16 | $487 |
| Janssen Pharmaceuticals, Inc | 17 | $440 |
| Teva Pharmaceuticals USA, Inc. | 26 | $410 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $364 |
| Alkermes, Inc. | 9 | $341 |
| Otsuka America Pharmaceutical, Inc. | 10 | $316 |
| Supernus Pharmaceuticals, Inc. | 7 | $258 |
| Axsome Therapeutics, Inc. | 7 | $258 |
Products named: FANAPT, VRAYLAR, INGREZZA, CAPLYTA, SPRAVATO, Auvelity, UZEDY, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
